Sigma Healthcare Ltd (SIG.AU) shares are soaring 5.32% in Wednesday's trading session following the release of its fiscal year 2025 financial results, which showcased significant revenue growth and a positive outlook for the company. The healthcare giant's strong performance and future prospects have evidently impressed investors, driving the stock's upward movement.

The company reported a substantial increase in revenue for the 12 months ended June 30, reaching AUD 6 billion, compared to AUD 3.29 billion in the previous year. This remarkable growth can be attributed to the recent merger with the Chemist Warehouse Group, which has significantly expanded Sigma's market presence. Despite a slight dip in earnings per share from AU$0.055 to AU$0.051, the company's normalised EBIT surged by 41.4% to $903.4 million, demonstrating improved operational efficiency.

Investors are particularly encouraged by Sigma's strong start to fiscal year 2026, with the company reporting double-digit like-for-like retail network sales growth year-to-date. This positive momentum, coupled with strategic initiatives such as the expansion of the Chemist Warehouse network and plans to optimize operations for cost savings, has bolstered confidence in Sigma's future performance. While the final dividend of AU$0.013 per share is lower than last year's AU$0.095, the market appears to be focusing on the company's growth trajectory and potential for long-term value creation.